

Author	Title	Year
Jeha	A phase II, open-label study of clofarabine in pediatric patients with refractory or relapsed acute-myelogenous or lymphoblastic leukemia	2003
Jeha	Clofarabine, A Novel Nucleoside Analog, Is Active in Pediatric Patients with Advanced Leukemia	2003
Jeha	Clofarabine, a novel nucleoside analog, is active in pediatric patients with advanced leukemia	2004
Jeha	Clofarabine therapy for the treatment of relapsed or refractory pediatric acute leukemias	2004
Kantarjian	Clofarabine-A New Nucleoside Analogue with Significant Activity in Leukemia	2002
Kantarjian	Phase I Clinical and Pharmacology Study of Clofarabine in Patients with Solid and Hematologic Cancers	2003
Kantarjian	Phase 2 clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia	2003
Kantarjian	Innovation in the management of AML and MDS	2004
Litzow	PNAs for AML	2003
Kozuch	Phase I Clinical and Pharmacological Study of Clofarabine	1999
Lindemalm	Comparison of cytotoxicity of 2-chloro-2'-arabino-fluoro-2'-deoxyadenosine (clofarabine) with cladribine in mononuclear cells from patients with acute myeloid and chronic lymphocytic leukemia	2003
Mansson	Resistance Mechanisms For Nucleoside Analogues	2002
Mansson	Down-Regulation of Deoxycytidine Kinase in Human leukemic Cell lines resistant to cladribine and clofarabine and increased ribonucleotide reductase activity contributes to fludarabine resistance	2003
Oncology News	Phase 1 Study of Clofarex Begun	2002
Plunkett	Targeting DNA Repair in Cancer Therapy	2004
UTMDACC	Leukemia Insights	2000
UTMDACC	Leukemia Insights	2002
Watson	Clofarabine shows antileukemic activity in pediatric setting	2004
Yamauchi	DAN repair Initiated in Chronic Lymphocytic Leukemia Lymphocytes by 4-Hydroperoxycyclophosphamide is Inhibited by Fludarabine and Clofarabine	2001
Zuiderduin	Joint 11 th International and 9 th European Symposium on Purines and Pyrimidines in Man (PP'03)	2003
No Authors Listed	Clofarabine	2004

Table of Contents

Author	Title	Year
Cheson	Hematologic Malignancies: New Developments and Future Treatments	2002
Chiao	Clofarabine-induced Acral Erythema During the Treatment of Patients with Myelodysplasia and Acute Leukemia: Report of Two Cases	2003
Cortes	Clofarabine {2-chloro-9-(2-deoxy-2-flouro-b-D-arabinofuranosyl) adenine} Is Active for Patients with Refractory or Relapsed Acute Leukemias, Myelodysplastic Syndromes (MDS) and Chronic Myeloid Leukemia in Blast Phase (CML-BP)	2002
Cunningham	A phase I dose-finding and safety study of clofarabine in patients with advanced solid malignancies	2003
Douer	Induction of Complete Remission using Single Agent Clofarabine in a Patient with Primary Refractory Acute Myeloblaste Leukemia	2003
Estey	New Designs for phase 2 clinical trials	2003
Estey	New Designs for Phase II trials: Application to a Trial of Targeted Therapies vs. Chemotherapy in Patients >60 with AML/High-Risk MDS	2004
Faderl	Clofarabine is active as a single agent and in combination with ara-C in patients (pts) with relapsed/refractory acute leukemias and high-risk myelodysplastic syndrome (MDS)	2003
Ferrara	Prognostic factors and therapeutic options for relapsed or refractory acute myeloid leukemia	2004
Foran	A phase II, open-label study of clofarabine in adult patients with refractory or relapsed acute myelogenous leukemia	2003
Gandhi	Clofarabine	2002
Gandhi	Pharmacokinetics and Pharmacodynamics of Plasma Clofarabine and Cellular Clofarabine Triphosphate in Patients with Acute Leukemias	2003
Giles	New Drugs in Acute Myeloid Leukemia	2002
Jeha	Clofarabine (Clofarex) is an active agent in pediatric leukemias	2002
Jeha	Phase I Study of Clofarabine (CLOFAREX™) in Pediatric Leukemia	2002
Jeha	A Phase II, Open-Label Study of CLOFARAX™ in Pediatric Patients with Refractory or Relapsed Acute-Myelogenous or Lymphoblastic Leukemia	2002
Jeha	A Phase II, Open-Label Study of Clofarabine in Pediatric Patients with Refractory or Relapsed Acute Myelogenous Leukemia	2003